Drugs / OncoLAR
OncoLAR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001436 | May 1995 → Sep 2000 | metastatic neoplasm, osteosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OncoLAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001436 ↗ |
| Known as | NSC 685403 | “A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma” NCT00001436 ↗ |
| Known as | SMS 201-955 pa LAR | “SMS 201-955 pa LAR is a long acting analog of Somatostatin which inhibits the pituitary release of growth hormone, reducing levels of circulating IGF-I .” NCT00001436 ↗ |
| Action | Inhibit | “inhibits the pituitary release of growth hormone, reducing levels of circulating IGF-I” NCT00001436 ↗ |
| Route | Other | “SMS 201-955 pa LAR injectable” NCT00001436 ↗ |